These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

415 related articles for article (PubMed ID: 15386310)

  • 1. Prognostic significance of serum osteoprotegerin levels in patients with bladder carcinoma.
    Mizutani Y; Matsubara H; Yamamoto K; Nan Li Y; Mikami K; Okihara K; Kawauchi A; Bonavida B; Miki T
    Cancer; 2004 Oct; 101(8):1794-802. PubMed ID: 15386310
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum syndecan-1, basic fibroblast growth factor and osteoprotegerin in myeloma patients at diagnosis and during the course of the disease.
    Kyrtsonis MC; Vassilakopoulos TP; Siakantaris MP; Kokoris SI; Gribabis DA; Dimopoulou MN; Angelopoulou MK; Pangalis GA
    Eur J Haematol; 2004 Apr; 72(4):252-8. PubMed ID: 15089762
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum osteoprotegerin (OPG) levels are associated with disease progression and response to androgen ablation in patients with prostate cancer.
    Eaton CL; Wells JM; Holen I; Croucher PI; Hamdy FC
    Prostate; 2004 May; 59(3):304-10. PubMed ID: 15042606
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High levels of osteoprotegerin and soluble receptor activator of nuclear factor kappa B ligand in serum of rheumatoid arthritis patients and their normalization after anti-tumor necrosis factor alpha treatment.
    Ziolkowska M; Kurowska M; Radzikowska A; Luszczykiewicz G; Wiland P; Dziewczopolski W; Filipowicz-Sosnowska A; Pazdur J; Szechinski J; Kowalczewski J; Rell-Bakalarska M; Maslinski W
    Arthritis Rheum; 2002 Jul; 46(7):1744-53. PubMed ID: 12124857
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sensitivity of prostate cells to TRAIL-induced apoptosis increases with tumor progression: DR5 and caspase 8 are key players.
    Hesry V; Piquet-Pellorce C; Travert M; Donaghy L; Jégou B; Patard JJ; Guillaudeux T
    Prostate; 2006 Jun; 66(9):987-95. PubMed ID: 16541419
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic significance of soluble Fas in the serum of patients with bladder cancer.
    Mizutani Y; Yoshida O; Bonavida B
    J Urol; 1998 Aug; 160(2):571-6. PubMed ID: 9679930
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic significance of orotate phosphoribosyltransferase activity in bladder carcinoma.
    Mizutani Y; Wada H; Fukushima M; Yoshida O; Nakanishi H; Li YN; Miki T
    Cancer; 2004 Feb; 100(4):723-31. PubMed ID: 14770427
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Osteoprotegerin is expressed in colon carcinoma cells.
    Pettersen I; Bakkelund W; Smedsrød B; Sveinbjørnsson B
    Anticancer Res; 2005; 25(6B):3809-16. PubMed ID: 16309167
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells.
    Shipman CM; Croucher PI
    Cancer Res; 2003 Mar; 63(5):912-6. PubMed ID: 12615702
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Concentration of osteoprotegerin (OPG) in peritoneal fluid is increased in women with endometriosis.
    Harada M; Osuga Y; Hirata T; Hirota Y; Koga K; Yoshino O; Morimoto C; Fujiwara T; Momoeda M; Yano T; Tsutsumi O; Taketani Y
    Hum Reprod; 2004 Oct; 19(10):2188-91. PubMed ID: 15242994
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum osteoprotegerin levels are increased in patients with advanced prostate cancer.
    Brown JM; Vessella RL; Kostenuik PJ; Dunstan CR; Lange PH; Corey E
    Clin Cancer Res; 2001 Oct; 7(10):2977-83. PubMed ID: 11595685
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Osteoprotegerin (OPG) expression by breast cancer cells in vitro and breast tumours in vivo--a role in tumour cell survival?
    Holen I; Cross SS; Neville-Webbe HL; Cross NA; Balasubramanian SP; Croucher PI; Evans CA; Lippitt JM; Coleman RE; Eaton CL
    Breast Cancer Res Treat; 2005 Aug; 92(3):207-15. PubMed ID: 16155791
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation of osteoprotegerin and sRANKL concentrations in serum and bone marrow of multiple myeloma patients.
    Kraj M; Owczarska K; Sokołowska U; Centkowski P; Pogłód R; Kruk B
    Arch Immunol Ther Exp (Warsz); 2005; 53(5):454-64. PubMed ID: 16314829
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of receptor activator of nuclear factor kappabeta ligand (RANKL) and tumour necrosis factor related, apoptosis inducing ligand (TRAIL) in breast cancer, and their relations with osteoprotegerin, oestrogen receptor, and clinicopathological variables.
    Cross SS; Harrison RF; Balasubramanian SP; Lippitt JM; Evans CA; Reed MW; Holen I
    J Clin Pathol; 2006 Jul; 59(7):716-20. PubMed ID: 16489180
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression and functional activity of osteoprotegerin in human malignant gliomas.
    Naumann U; Wick W; Beschorner R; Meyermann R; Weller M
    Acta Neuropathol; 2004 Jan; 107(1):17-22. PubMed ID: 14504888
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells.
    Holen I; Croucher PI; Hamdy FC; Eaton CL
    Cancer Res; 2002 Mar; 62(6):1619-23. PubMed ID: 11912131
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histone deacetylase inhibitors modulate the sensitivity of tumor necrosis factor-related apoptosis-inducing ligand-resistant bladder tumor cells.
    Earel JK; VanOosten RL; Griffith TS
    Cancer Res; 2006 Jan; 66(1):499-507. PubMed ID: 16397266
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TNF-related apoptosis-inducing ligand and its decoy receptor osteoprotegerin in nonischemic dilated cardiomyopathy.
    Schoppet M; Ruppert V; Hofbauer LC; Henser S; Al-Fakhri N; Christ M; Pankuweit S; Maisch B
    Biochem Biophys Res Commun; 2005 Dec; 338(4):1745-50. PubMed ID: 16288714
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High serum values of soluble CD154, IL-2 receptor, RANKL and osteoprotegerin in Langerhans cell histiocytosis.
    Ishii R; Morimoto A; Ikushima S; Sugimoto T; Asami K; Bessho F; Kudo K; Tsunematu Y; Fujimoto J; Imashuku S
    Pediatr Blood Cancer; 2006 Aug; 47(2):194-9. PubMed ID: 16358318
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical use of serum CA-125 levels in patients undergoing radical cystectomy for transitional cell carcinoma of the bladder.
    Kouba EJ; Lentz A; Wallen EM; Pruthi RS
    Urol Oncol; 2009; 27(5):486-90. PubMed ID: 18555706
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.